𝔖 Bobbio Scriptorium

✦ LIBER ✦

[Advances in Immunology] Advances in Immunology Volume 98 Volume 98 || Chapter 4 B Cells and Autoantibodies in the Pathogenesis of Multiple Sclerosis and Related Inflammatory Demyelinating Diseases

✍ Scribed by McLaughlin, Katherine A.

Book ID: 120201222
Publisher: Elsevier
Year: 2008
Tongue: English
Weight: 592 KB
Category: Article
ISBN: 0123743311
ISSN: 0065-2776
DOI: 10.1016/S0065-2776(08)00404-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[Advances in Immunology] Advances in Imm

[Advances in Immunology] Advances in Immunology Volume 98 Volume 98 || Chapter 1 Immune Regulation by B Cells and Antibodies

✍ Hoehlig, Kai 📂 Article 📅 2008 🏛 Elsevier 🌐 English ⚖ 365 KB

*Advances in Immunology,* a long-established and highly respected publication, presents current developments as well as comprehensive reviews in immunology. Articles address the wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molec

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Advances in multiple Sclerosis and Experimental Demyelinating Diseases Volume 318 || Immunological Aspects of Axon Injury in Multiple Sclerosis

✍ Rodriguez, Moses 📂 Article 📅 2008 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 296 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Advances in multiple Sclerosis and Experimental Demyelinating Diseases Volume 318 || Role of Uric Acid in Multiple Sclerosis

✍ Rodriguez, Moses 📂 Article 📅 2008 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 200 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Advances in multiple Sclerosis and Experimental Demyelinating Diseases Volume 318 || The Multiple Sclerosis Degradome: Enzymatic Cascades in Development and Progression of Central Nervous System Inflammatory Disease

✍ Scarisbrick, I. A. (author) 📂 Article 📅 2008 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 230 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Advances in multiple Sclerosis and Experimental Demyelinating Diseases Volume 318 || The Multiple Sclerosis Degradome: Enzymatic Cascades in Development and Progression of Central Nervous System Inflammatory Disease

✍ Scarisbrick, I. A. (author) 📂 Article 📅 2008 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 230 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Advances in multiple Sclerosis and Experimental Demyelinating Diseases Volume 318 || Remyelination in Experimental Models of Toxin-Induced Demyelination

✍ Rodriguez, Moses 📂 Article 📅 2008 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 582 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people